Search clinical trials for: EQU-001

Total 4301 results

NantBioScience, Inc.

Active, not recruiting

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Melanoma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Liver Cancer

United States
Andrew Sikora
Advaxis, Inc.

Completed

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
BiondVax Pharmaceuticals ltd.
Seventh Framework Programme

Completed

Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults

Healthy | Influenza

Hungary
Yungjin Pharm. Co., Ltd.

Completed

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
MitoImmune Therapeutics

Completed

Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

Heathly Subjects

Korea, Republic of
Alumis Inc

Recruiting

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus (LUMUS)

SLE

United States, Argentina, Bulgaria, Colombia, Georgia, India, Mexico, Peru, Philippines, Poland, Spain, United Kingdom, Croatia, Denmark, Germany, Hungary, Korea, Republic of, Romania, Taiwan, Chile
X4 Pharmaceuticals

Active, not recruiting

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Neutropenia

United States
OXOLIFE

Completed

Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes. (OXOART2)

Infertility | Infertility, Female

Czechia, Spain, Poland
Red Queen Therapeutics, Inc.
PPD

Completed

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

COVID-19 | Infectious Disease | SARS CoV 2 Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Regeneron Pharmaceuticals

Available

Compassionate Use of Vidutolimod
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

China
Sarkana Pharma Inc

Terminated

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

Healthy Participants

Netherlands
Yaqrit Ltd
Assistance Publique - Hôpitaux de Paris; IRCCS Azienda Ospedaliero-Universitaria... and other collaborators

Withdrawn

Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

France, Italy, Portugal, Spain, Switzerland, United Kingdom
Bioventus LLC

Active, not recruiting

Safety Study of PTP-001 for Treating Knee Osteoarthritis

Knee Osteoarthritis

United States
Pfizer

Completed

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Scar Prevention

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Scar Prevention

United States
Vasomune Therapeutics, Inc.

Completed

A First-in-Human Study of AV-001 in Healthy Subjects

Covid19 | ARDS | Covid19-associated ARDS

United States
Balance Therapeutics

Completed

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Idiopathic Hypersomnia | Narcolepsy Without Cataplexy

United States
Balance Therapeutics

Completed

A Study to Investigate the Mass Balance of BTD-001 (HV103)

Molecular Mechanisms of Pharmacological Action

United Kingdom
Xenon Pharmaceuticals Inc.

Completed

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Dental Pain

United States
Abbott

Completed

A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency

Exocrine Pancreatic Insufficiency, Chronic Pancreatitis

Japan
Latigo Biotherapeutics

Recruiting

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

New Zealand
MedRegen LLC

Recruiting

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Wound of Skin | Abdominal Wound

United States
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness

Active, not recruiting

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (SLO RP)

Usher Syndromes

Australia
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Anebulo Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Acute Cannabinoid Intoxication

Netherlands
Bloom Science

Completed

A Phase Ia Safety and Tolerability Study of BL-001

Healthy Volunteers

Switzerland
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Netherlands, United Kingdom, Czechia, Portugal, Hungary
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Perianal Fistula

Rectal Fistula
Cure Rare Disease, Inc
University of Massachusetts, Worcester

Active, not recruiting

Treatment of a Single Patient With CRD-TMH-001

Duchenne Muscular Dystrophy

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Completed

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

COVID-19

China
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Novo Nordisk A/S

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Anemia

United States
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
Olympus Corporation

Terminated

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Emphysema

Japan
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Viridian Therapeutics, Inc.

Not yet recruiting

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States
Biokuris s.a.

Recruiting

A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

Belgium
Entos Pharmaceuticals Inc.
Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical Pharma... and other collaborators

Completed

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults

SARS-CoV-2

Burkina Faso, Canada, Senegal, South Africa
University of Alabama at Birmingham
Wm. Wrigley Jr. Company

Completed

Chewing Gum for Weight Loss

Obesity | Overweight | Weight Loss

United States
Allyx Therapeutics
Michael J. Fox Foundation for Parkinson's Research

Recruiting

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

Parkinson Disease

United States
Pharmasaga Co. Ltd.

Recruiting

Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

Type II Diabetes

Taiwan
Cynata Therapeutics Limited
Cerebral Palsy Alliance

Completed

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND)

Covid19 | Acute Respiratory Distress Syndrome

Australia
X4 Pharmaceuticals

Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Waldenstrom's Macroglobulinemia

United States, Greece
PTC Therapeutics

Completed

A Study of CNSA-001 in Women With Diabetic Gastroparesis

Gastroparesis

United States
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
Cloudbreak Therapeutics, LLC

Completed

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium (Pterygium)

Pterygium

United States

Search clinical trials for: EQU-001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations